{"id":851857,"date":"2025-05-16T08:05:32","date_gmt":"2025-05-16T12:05:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/"},"modified":"2025-05-16T08:05:32","modified_gmt":"2025-05-16T12:05:32","slug":"iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/","title":{"rendered":"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials<\/b><\/p>\n<p>RESEARCH TRIANGLE PARK, N.C.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nIQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients.\n<\/p>\n<p>\nThe collaboration leverages IQVIA\u2019s global reach and precision in managing one in five oncology trials in the United States, along with its ability to seamlessly integrate data, technology and analytics. These capabilities are combined with SCRI Development Innovations&#8217; community oncology expertise, and enhanced operational model, Accelero, which expedites trial activation and enhances recruitment for SCRI sites in the United States. Additionally, the Accelero model seamlessly integrates data from the electronic health record to the electronic data capture systems for U.S. clinical trial data collection. Together, these strengths offer sponsors a more effective pathway to operationalize the development of innovative treatments for patients.\n<\/p>\n<p>\n\u201cWe are excited to announce our collaboration with SCRI Development Innovations,\u201d said Richard Staub, president of Research &amp; Development Solutions at IQVIA. \u201cThis collaboration embodies our commitment to innovation, efficiency and delivering of superior outcomes for patients by bringing together the best of both organizations and eliminating the complexities often associated with multiple vendors. Together we will accelerate the development of new cancer therapies and improve outcomes for patients worldwide.\u201d\n<\/p>\n<p>\n\u201cWe are enthusiastic about the impact we can make in transforming clinical trial delivery through our collaboration with IQVIA,\u201d said Dee Anna Smith, chief executive officer at Sarah Cannon Research Institute. \u201cThrough our accelerated operations model, Accelero, SCRI can alleviate the operational burden on research sites, enhance enrollment and expedite data delivery through our cutting-edge technology solutions. Additionally, we will leverage IQVIA\u2019s global reach, expertise and capabilities in trial design and recruitment to provide a seamless global delivery model for our partners.\u201d\n<\/p>\n<p>\nThe collaboration between IQVIA and SCRI Development Innovations marks a significant step forward in transforming oncology trial delivery globally. Visit IQVIA at Booth 14103 or SCRI at Booth 27022 during the American Society of Clinical Oncology (ASCO) Annual Meeting May 30 to June 3 in Chicago, Ill., to learn more about this innovative partnership to advance cancer research and improve patient outcomes.\n<\/p>\n<p><b>About IQVIA<\/b><\/p>\n<p>\nIQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA\u2019s portfolio of solutions are powered by IQVIA Connected Intelligence\u2122 to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI<sup>\u00ae<\/sup>, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.\n<\/p>\n<p><b>About Sarah Cannon Research Institute<\/b><\/p>\n<p>\nSarah Cannon Research Institute (SCRI) is one of the world\u2019s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI\u2019s research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S. Visit scri.com to learn more.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250516891083\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250516891083\/en\/<\/a><\/span><\/p>\n<p><b>Media Contacts<br \/>\n<\/b><br \/>IQVIA:<br \/>\n<br \/>Kerri Joseph, IQVIA Investor Relations (<a rel=\"nofollow\" href=\"mailto:kerri.joseph@iqvia.com\">kerri.joseph@iqvia.com<\/a>) +1.973.541.3558<br \/>\n<br \/>Alissa Maupin, IQVIA Media Relations (<a rel=\"nofollow\" href=\"mailto:alissa.maupin1@iqvia.com\">alissa.maupin1@iqvia.com<\/a>) +1.919.923.6785\n<\/p>\n<p>\nSCRI:<br \/>\n<br \/>Becca Gelman, Marketing &amp; Public Relations (<a rel=\"nofollow\" href=\"mailto:Becca.Gelman@scri.com\">Becca.Gelman@scri.com<\/a>)\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America North Carolina<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Clinical Trials Health Technology Software Biotechnology Health Data Management Artificial Intelligence Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250516891083\/en\/2471813\/3\/72aec067-62d2-4e04-93fc-92b8c5b529fe.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients. The collaboration leverages IQVIA\u2019s global reach and precision in managing one in five oncology trials in the United States, along with its ability to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-851857","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients. The collaboration leverages IQVIA\u2019s global reach and precision in managing one in five oncology trials in the United States, along with its ability to &hellip; Continue reading &quot;IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T12:05:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials\",\"datePublished\":\"2025-05-16T12:05:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/\"},\"wordCount\":739,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/\",\"name\":\"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-05-16T12:05:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/","og_locale":"en_US","og_type":"article","og_title":"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Market Newsdesk","og_description":"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials RESEARCH TRIANGLE PARK, N.C.&#8211;(BUSINESS WIRE)&#8211; IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Innovations, this collaboration will enhance clinical trial processes, eliminate operational hurdles, accelerate data delivery and expedite the availability of cutting-edge therapies to patients. The collaboration leverages IQVIA\u2019s global reach and precision in managing one in five oncology trials in the United States, along with its ability to &hellip; Continue reading \"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-16T12:05:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials","datePublished":"2025-05-16T12:05:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/"},"wordCount":739,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/","name":"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-05-16T12:05:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250516891083r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-and-scri-collaborate-to-accelerate-global-oncology-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=851857"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851857\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=851857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=851857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=851857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}